MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3] - The company has a late-stage pipeline that includes 11 clinical programs, primarily centered around two compounds: MN-166 (ibudilast) and MN-001 (tipelukast) [3] - MN-166 (ibudilast) is currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS) [3] Clinical Trials - An abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in ALS patients has been selected for a poster presentation at the 36th International Symposium on ALS/MND scheduled for December 5-7, 2025 [1][2] - The presentation will cover trial updates and baseline characteristics, indicating ongoing progress in the clinical development of MN-166 [2] Product Information - MN-166 (ibudilast) is a small molecule that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, and is being developed for various neurodegenerative diseases, including ALS, progressive MS, and DCM [2] - The compound is also under investigation for other conditions such as glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder [2]